Ribavirin Litigation Set To Rest: Valeant's Appeal In Patent Case Dismissed
This article was originally published in The Pink Sheet Daily
Valeant requested the dismissal. The company's appeal was largely premised on FDA approval of a citizen petition concerning ribavirin generics' ability to "carve out" protected labeling; the agency denied the petition in April.
You may also be interested in...
Schering generic launches April 8, two days after FDA clears Three Rivers’ and Sandoz’ ribavirin ANDAs. All generics are expected to be priced at a 10% discount to Schering’s Rebetol.
Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.